Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'd guess it's about another 100K.
https://www.advaxis.com/news-releases/news-release-details/advaxis-announces-receipt-second-milestone-payment-under-adxs
Advaxis Announces Receipt of Second Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies
April 26, 2021
Non-dilutive capital to support advancement of ADXS-HOT neoantigen program
PRINCETON, N.J., April 26, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company has received the second milestone payment related to its licensing agreement for ADXS31-164, also known as ADXS-HER2, to OS Therapies for evaluation in the treatment of osteosarcoma in humans.
Under the terms of the license agreement, OS Therapies, in collaboration with the Children’s Oncology Group (COG), is responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. OS Therapies recently completed a financing, triggering the second milestone payment. Under the agreement, Advaxis has the opportunity to receive additional clinical, regulatory, and sales-based milestone payments as well as royalties on future product sales. Additional details of the financial terms have not been disclosed.
“This funding milestone for OS Therapies brings OST-HER2, originally ADXS-HER2, one step closer to the clinic,” said Kenneth A. Berlin, President and Chief Executive Officer of Advaxis. “We are confident in the potential of OST-HER2, which had been approved in the U.S. for the adjuvant treatment of osteosarcoma in canines, and are proud to have played a role in the development of this important new candidate for osteosarcoma patients. We look forward to the team at OST advancing the program, building upon our early Phase 1 data evaluating ADXS-HER2.”
Mr. Berlin continued, “This milestone payment provides Advaxis additional capital as we build momentum across our growing ADXS-HOT neoantigen-directed off-the-shelf clinical programs. To date, we have assembled a robust clinical and translational data set which suggests our unique approach has the potential to enhance and/or restore responses to checkpoint inhibitors in lung cancer. We look forward to leveraging these resources as we advance ADXS-503, currently being evaluated in our Phase 1/2 study in NSCLC, and ADXS-504 for early-stage prostate cancer, which is on-track to enter the clinic in Q2 2021.”
The management team will be doing a R/S very soon. I doubt they want to go through a pain of getting the non-compliance and delisting notice. And everyone playing ball knows this. Therefore, more aggressive shorting.
So, tell us why the share price's been dropping like a rock? Where are the "$0.79 price supporters"? Why no show? You and I all know the answer well --nobody "paid" that price and intended to do so. These "buyers" shorted at much higher prices and will be waiting the SP to drop to 30s or 20s to cover with free shares.
Well, if you run the 0.70 warrants set to expire in 5years through the Black-Sholes calculator, you could see that the real price for these share/warrant combos is close to 35cents. That's the share price attractor and it's where the SP is going to go. I suspect we overshoot that target by ten or 15 cents, and "hello, twenties!".
I'm pretty sure the 0.70 warrants will be repriced in a short while once the SP hits 0.30s. This is no better than the direct offering, regardless of what you state. Dilution is dilution.
Here it comes...
https://finance.yahoo.com/news/advaxis-inc-announces-20-million-123000787.html
Advaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Mon, April 12, 2021, 8:30 AM
PRINCETON, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it has entered into definitive agreements with two healthcare-focused, institutional investors for the purchase of (i) 17,577,400 shares of common stock , (ii) 7,671,937 pre-funded warrants (the “Pre-Funded Warrants”) to purchase 7,671,937 shares of common stock and (iii) registered common share purchase warrants to purchase 11,244,135 shares of common stock. The Company has also agreed to issue to the investors, in a concurrent private placement, unregistered common share purchase warrants to purchase 14,005,202 shares of the Company’s common stock. Each share of common stock and accompanying common share purchase warrant are being sold together at a combined offering price of $0.7921, and each Pre-funded Warrant and accompanying common warrant are being sold together at a combined offering price of $0.7911, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules. The Pre-Funded Warrants are immediately exercisable, at an exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The registered common share purchase warrants will have an exercise price of $0.70 per share, will be immediately exercisable, and will expire five (5) years from the date of issuance. The unregistered common share purchase warrants will have an exercise price of $0.70 per share, will be exercisable fourteen days after the Company increases its authorized share capital, and will expire five (5) years from their initial exercise date (collectively, the “Offering”).
The Company plans to use the net proceeds from the offering to fund its continued research and development initiatives in connection with expanding its product pipeline including, but not limited to, investment in its ADXS-HOT program and for general corporate purposes. The Company may also use a portion of the net proceeds to acquire or invest in other businesses, products and technologies.
A.G.P./Alliance Global Partners is acting as sole placement agent for the Offering.
The Offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-226988) previously filed with the U.S. Securities and Exchange Commission (the “SEC”), and an additional registration statement on Form S-3 filed pursuant to Rule 462(b) under the Securities Act, which became effective upon filing on August 30, 2018. A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022 or via telephone at 212-624-2060 or email: prospectus@allianceg.com. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering. Copies of the Supplement, the Base Shelf Prospectus and the Registration Statement may also be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022 or via telephone at 212-624-2060 or email: prospectus@allianceg.com.
No securities regulatory authority has either approved or disapproved of the contents of this press release. This press release is for information purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Advaxis
Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.
from the PR:
That's a stunning transformation -- from hornet nest to dragon fly...
didn't they say it's an IST -- investigator sponsored trial?
https://www.advaxis.com/news-releases/news-release-details/advaxis-announces-agreement-columbia-university-irving-medical
Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer
April 5, 2021
Initiation of Phase 1 study in biochemically recurrent prostate cancer anticipated in Q2
PRINCETON, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced an agreement with Columbia University Irving Medical Center to fund a Phase 1 clinical study evaluating ADXS-504 in patients with biochemically recurrent prostate cancer. The study, expected to begin in Q2 2021, will be the first clinical evaluation of ADXS-504, Advaxis’ off-the-shelf neoantigen immunotherapy drug candidate for early prostate cancer. Mark Stein, M.D., associate professor of medicine in the Division of Hematology/Oncology at Columbia University Vagelos College of Physicians and Surgeons, will be the study’s principal investigator.
The Phase 1 open-label study will evaluate the safety and tolerability of ADXS-504 monotherapy, administered via infusion, in 9-18 patients with biochemically recurrent prostate cancer, i.e., those with elevation of prostate-specific antigen (PSA) in the blood after radical prostatectomy or radical radiotherapy (external beam or brachytherapy) and who are not currently receiving androgen ablation therapy. The study will also evaluate preliminary clinical and immune responses following treatment with ADXS-504 monotherapy.
Nearly 248,530 men in the United States will be diagnosed with prostate cancer in 2021, and approximately 34,130 will die from this disease. Many more men with prostate cancer will experience rising prostate-specific antigen (PSA) levels following local therapy with radical radiotherapy or prostatectomy, a condition known as biochemical recurrence (BCR). BCR is not typically associated with imminent death, and biochemical progression may occur over a prolonged period. Clinicians treating men with BCR thus face a difficult set of decisions in attempting to delay the onset of metastatic disease and death while avoiding over-treating patients whose disease may never affect their overall survival or quality of life.
“Currently, men with biochemically recurrent prostate cancer are either monitored for a period of time without intervention or may be started on medicine to decrease the level of testosterone in the body, which can have significant side effects,” said Dr. Stein. “Therefore, we need new approaches to stimulate the body’s immune system to control the prostate cancer. Given the encouraging results from a Phase 2 study of ADXS-PSA, which targets a single-antigen, in combination with KEYTRUDA®, in men with advanced prostate cancer, and emerging signals of potential clinical activity of the Company’s multi-antigen technology in non-small cell lung cancer, we are excited to have the opportunity to explore the potential of ADXS-504 immunotherapy as a novel treatment modality for biochemically recurrent prostate cancer.”
ADXS-504 is a novel Lm-based immunotherapy, bioengineered to elicit T cell responses against 24 tumor antigens that include 14 peptide antigens derived from frequently occurring and commonly shared hotspot mutations in patients with prostate cancer and 10 peptide antigens derived from sequence-optimized tumor-associated antigens (TAAs) that are differentially expressed or overexpressed in prostate cancer. ADXS-504 is designed to express multiple tumor antigen targets to which patients may generate a broad set of effector T cells for tumor control. Similar to Advaxis’ other Lm-based immunotherapies, ADXS-504 is expected to induce an innate immune response followed by the adaptive response and modification of the immunosuppressive tumor microenvironment (TME) by reducing regulatory T cells (Tregs) and myeloid-derived suppressor cell (MDSC) frequencies in the TME.
Kenneth A. Berlin, President and Chief Executive Officer of Advaxis said, “We are pleased to be working with Columbia University Irving Medical Center to conduct the first clinical evaluation of ADXS-504 in earlier stages of prostate cancer where drug constructs of this type could potentially control micrometastasis efficiently. The strategic decision to transition the ADXS-504 to an investigator-sponsored study at Columbia will provide access to world-class expertise and has the potential to accelerate patient recruitment in order to expedite our clinical progress. We are encouraged by our momentum and look forward to continued progress across our ADXS-HOT program, which also includes ongoing studies in NSCLC in the first line setting and in patients who have progressed on pembrolizumab.”
About Advaxis
Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are any statements that express the current beliefs and expectations of management. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. Such risks include, but are not limited to: the success and timing of the Company’s clinical trials, including patient accrual; the Company’s ability to develop and commercialize its products; the Company’s ability to identify license and collaboration partners and to maintain existing relationships; the Company’s available cash and its ability to obtain additional funding; and any outcomes from the Company’s review of strategic transactions. These and other risks are discussed in the Company’s filings with the SEC, including, without limitation, its Annual Report on Form 10-K, filed on December 20, 2019, as amended, and its periodic reports on Form 10-Q and Form 8-K. The Company cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date they were made. The Company undertakes no obligation to update or revise forward-looking statements whether as a result of new information, future events or otherwise, except as otherwise required by law.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA.
Contact:
Tim McCarthy, LifeSci Advisors, LLC
212.915.2564
tim@lifesciadvisors.com
This is a virtual BYOB event followed by another BOGO for "Friends and Family". These bloodsuckers are to almost double the number of authorized shares from 170MM to 300MM, to approve a "point-n-click" reverse split w/o any further "stockholders" approval. They want to increase the number of RSUs by a factor of 7 and remove the max number of shares they can grant to themselves. Why not? This is far beyond of any hope for repairs. This company is done. Shorting will be non-stop for the next 2 months and beyond.
So, what was her last appearance? Just a rehearsal? Was she singing a lullaby to a Kenny boy? That fat lady will be booed...
No way, not this Friday, anyway. The markets are closed tomorrow. Shooting for today or for the next Friday.
If ADXS were to correlate with XBI (or IBB) index, ADXS stock would have been over $10,000 after post-post...-split. But you obviously are well aware of the current share price, aren't you?
Looks like the presentation went really well -- we're just 4% down. Ken, you certainly deserved your 2020 bonus. I'm really excited to watch you and the company doing a great job by "following the science of Advaxis". Is Dr Fauci on your Science Advisory Board now? Money well spent!
Yes, they appear to lease. I found myself surprised to see this from the recent 10Q:
New CP is up:
https://www.advaxis.com/static-files/4ec9466a-4000-498e-ab5b-743641551646
I can't believe this company with a headcount of 20 burns more than $11M/year -- that's over $550K/person per year in G/A expenses! That's insane!
They're burning almost $27MM/year, while their cash is just over $33MM. They'll be running another secondary this summer, at the latest. Share count is going to balloon to 200MM. Think of that! This is after how many reverse splits? Does anyone keep the count?
Operating Expenses for the Year Ended October 31, 20201
Research and Development Expenses2 $15.6MM
General and Administrative Expenses2 $11.1MM
Positive Cash Balance Anticipated Into Fiscal Q3 2022
Cash, Cash Equivalents and Marketable Securities, as of January 31, 2021 $ 33.3MM
Could have been us...
Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash
https://finance.yahoo.com/news/amgen-acquire-five-prime-therapeutics-133000416.html
Sapporo without Batemere is just a glass of sake diluted with donkey piss. Is he okay, btw?
B:
you need to take a chill pill. No need to get angry for me showing up here.
I asked a question to get a short answer and did not get it. Instead, I got your angry rant.
There's nothing going on here expect for a cyclical P&D. I just happen to miss the 1st part of that cycle, now the "D" part starts. Nothing new. KB hired a new guy to hide his shenanigans. Again, they come and go. What doesn't change is the stink emanating from the corpse of ADXS.
Haven't been around for a couple of weeks and we're over a buck? What's going on? Don't see any news though. Did I miss the NEWS?
De nada.
I don't think so. From 10-K:
No news? I'd guess this run could be attributed (at least, partially) to the failure of GSK/Merck Serono's bintrafusp alfa for NSCLC. They might be looking for a potential candidate to replace that failed drug. HOT could be that candidate.
https://endpts.com/glaxosmithklines-4b-bispecific-cancer-drug-alliance-with-merck-kgaa-rattled-by-a-trial-flop-for-nsclc/
Guessing it's about 15K? Enough to cover KB's trip to Caymans?
https://finance.yahoo.com/news/advaxis-announces-receipt-funding-milestone-130000284.html
Buyout? Have we not heard that before multiple times? It's been a constant narrative for many years now just as a bankruptcy lately. The only variable has been the big pharma name that'll buys us out.
Heisenberg? Next room from our former padded cell? Do you still stay in touch with him? Is he finally out?
If Kenny splits atoms into protons, neutrons and electrons in just few pico seconds, watch out how routinely he’ll do a reverse split of an Advaxis stock. As a bonus, we as Advaxis shareholders get one boson per share. I am already looking for a box to store 77,067 bosons.
Anyone consider participating in the class action lawsuit by an ambulance chaser Fields, Kupka and Shukurov? I definitely will consider this avenue but does it have any prospects?
It's time to turn BadWaxIs into MadVaxis!
Mad dash to 0.33 and beyond!
Blue Eye Capital Pvt relocated to the Tuamotu Islands and got rebranded as BlackIcatchers Ltd.
inflation ...
2/3 of the entire float traded now and the ratio will be higher before the close. The market cap is under $20M. This stock has been under a full control of shorts and manipulators for years. The company is done, and Ken must be sued together with Sideratskiy. Twenty years of a daily electric chair is a fair punishment for their crimes.
PS. Electric chair can be replaced with the guillotine albeit the former is more environmental friendly.
It's possible they'd run in up to 35 or above once the SP hits low 20's first. Why not? They could make money by running it either way.
Kenny bought himself another 6 months or so to collect a bloated paycheck and get a well-deserved cash bonus for Hanukkah. Why not, again? They'll be trying to sell this POS by next summer or autumn. 15MM for ADXS? Ken will get another bonus for doing that. Life is full of surprises.
Looks like they're doing just fine...
as expected -- this is going to hit (low) twenties soon. They've been trying to pump this POS for almost a month now, and here it comes.
... and Ken gets his Hanukkah bonus.
Another dilution...
Advaxis, Inc. Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
Go Back
November 23, 2020
Download PDF
PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. In connection with the offering, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock and/or purchase warrants to purchase additional shares of common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the size or terms of the proposed offering.
The Company plans to use the net proceeds from the offering to fund its continued research and development initiatives in connection with expanding its product pipeline including, but not limited to, investment in its ADXS-HOT program and for general corporate purposes. The Company may also use a portion of the net proceeds to acquire or invest in other businesses, products and technologies.
A.G.P./Alliance Global Partners is acting as sole book-running manager for the offering.
This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-226988) previously filed with the U.S. Securities and Exchange Commission (the “SEC”), and an additional registration statement on Form S-3 filed pursuant to Rule 462(b) under the Securities Act, which became effective upon filing on August 30, 2018. A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022 or via telephone at 212-624-2060 or email: prospectus@allianceg.com. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering. Copies of the Supplement, the Base Shelf Prospectus and the Registration Statement may also be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022 or via telephone at 212-624-2060 or email: prospectus@allianceg.com.
No securities regulatory authority has either approved or disapproved of the contents of this press release. This press release is for information purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.